{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Focus on variants of genes in the pathway targeted by cediranib maleate, including kdr/flk-1 (the specific target of cediranib maleate) and the genes that encode Vascular endothelial growth factor A (VEGF-A) or HIF1α. If additional information relevant to other genes of interest in the pathway becomes available the samples will be utilized for such analysis as well.","groups":[{"description":"Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.","id":"OG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"populationDescription":"This outcome was not measured/assessed for any of the study subjects.","reportingStatus":"POSTED","timeFrame":"Week 1 of course 1","title":"Pharmacogenomics by Correlating Genetic Polymorphisms With Drug Activity and Toxicity","type":"SECONDARY"}